Jesús
Fortun Abete
Profesor/a Asociado/a en CC. de la Salud
Esperanza
Merino de Lucas
Publicaciones en las que colabora con Esperanza Merino de Lucas (10)
2024
-
A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 79, Núm. 4, pp. 910-919
-
Corrigendum to “Safety and effectiveness of isavuconazole in real-life non-neu tropenic patients” [International Journal of Infectious Diseases 144 (2024) 107070] (International Journal of Infectious Diseases (2024) 144, (S1201971224001413), (10.1016/j.ijid.2024.107070))
International Journal of Infectious Diseases
-
Safety and effectiveness of isavuconazole in real-life non-neutropenic patients
International Journal of Infectious Diseases, Vol. 144
2021
2018
-
Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation
Clinical Microbiology and Infection, Vol. 24, Núm. 2, pp. 192-198
2017
-
Cytomegalovirus infection management in solid organ transplant recipients across European centers in the time of molecular diagnostics: An ESGICH survey
Transplant Infectious Disease, Vol. 19, Núm. 6
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Clinical Presentation and Determinants of Mortality of Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: A Multinational Cohort Study
American Journal of Transplantation, Vol. 16, Núm. 11, pp. 3220-3234
-
Risk Factors Associated With Early Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: Results From a Multinational Matched Case–Control Study
American Journal of Transplantation, Vol. 16, Núm. 7, pp. 2148-2157
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784